• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage. Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news

Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

The current and potential health benefits of the National Health Service Health Check cardiovascular disease prevention programme in England: A microsimulation study
ConclusionsOur model indicates that the current NHS Health Check programme is contributing to improvements in health and reducing health inequalities. Feasible changes in the organisation of the programme could result in more than a 3-fold increase in health benefits.
Source: PLoS Medicine - March 6, 2018 Category: Internal Medicine Authors: Oliver T. Mytton Source Type: research

Correlation between use of simvastatin and lovastatin and female lung cancer risk: a nationwide case-control study.
CONCLUSIONS: Simvastatin use at a DDD of more than 150 is correlated with an approximately 20% reduction in the risk of lung cancer in women. PMID: 25421876 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - November 25, 2014 Category: Cancer & Oncology Authors: Yang TY, Lin WM, Lin CL, Sung FC, Kao CH Tags: Int J Clin Pract Source Type: research

Correlation between use of simvastatin and lovastatin and female lung cancer risk: a nationwide case–control study
ConclusionsSimvastatin use at a DDD of more than 150 is correlated with an approximately 20% reduction in the risk of lung cancer in women.
Source: International Journal of Clinical Practice - November 25, 2014 Category: Internal Medicine Authors: T.‐Y. Yang, W.‐M. Lin, C.‐L. Lin, F.‐C. Sung, C.‐H. Kao Tags: Original Paper Source Type: research